Compound Screening Libraries

Optimized for Disease Mechanism Revealing & Drug Repurposing

- Bioactive Compound Library
- FDA-Approved Drug Library
- Anti-Cancer Compound Library
- Kinase Inhibitor Library
- Small Molecule Immuno-Oncology Compound Library
- GPCR/G Protein Compound Library
- Epigenetics Compound Library
- Anti-Infection Compound Library
- Clinical Compound Library
- CNS-Penetrant Compound Library

Virtual Screening

www.MedChemExpress.com

- Inhibitors
- Agonists
- Screening Libraries
Bioactive Compound Screening Libraries
(96- or 384-well)

Our ready-to-use MedChemExpress (MCE) compound libraries consist of over 7,000 small molecules with validated biological and pharmacological activities. They are available for high-throughput screening (HTS) and high-content screening (HCS). Compound libraries are useful professional tools for drug discovery and new indication research.

- **Safety** and effectiveness have been confirmed by literature, patent reports and clinical research. Many products are FDA-approved.

- Focuses on hundreds of targets that are key components in the fields of GPCR, kinase, anti-cancer, epigenetics, stem cell biology, etc.

- Up-to-date with the latest medical molecule developments and offers access to our exclusive Clinical Compound Library.

- Detailed biological and chemical information are provided for every compound together with the LC/MS and NMR reports to ensure high quality.

We offer over 300 exclusive compounds worldwide and track the latest scientific innovations to give our customers access to the newest small molecules. We are dedicated to providing high-quality small molecules to our customers around the world.

Customize Your Library

MCE offers customized compound libraries based on your specific needs.

You can select compounds, format (powder/liquid), size and plate map depending on your requirements.

Specific Compounds

Quantities

Plate Map

Concentration

Format (Dry/solid or DMSO Solution)
Publications Citing Use of MCE Products

Cell. 2018 Sep 20;175(1):186-199.e19.
Nat Med. 2018 Sep;24(9):1395-1406.

... See more citations on www.MedChemExpress.com
MCE Screening Library Partners
# Table of Contents

## MCE Screening Libraries:

- Bioactive Compound Library ........................................... 01
- Bioactive Compound Library Plus ........................................ 02
- Fragment Library ......................................................... 03

## According to Clinical Data:

- FDA-Approved Drug Library ............................................ 04
- FDA-Approved Drug Library Mini ........................................ 05
- Clinical Compound Library ............................................. 06

## According to Disease Types:

- Anti-Cancer Compound Library ........................................ 07
- Small Molecule Immuno-Oncology Compound Library ........ 08
- Anti-Infection Compound Library ..................................... 09
- Anti-Virus Compound Library ......................................... 10

## According to Signaling Pathway or Protein Family:

- Kinase Inhibitor Library ................................................ 15
- Apoptosis Compound Library .......................................... 16
- Autophagy Compound Library .......................................... 17
- Cell Cycle/DNA Damage Compound Library ....................... 18
- Epigenetics Compound Library ........................................ 19
- GPCR/G Protein Compound Library .................................. 20
- Histone Modification Research Compound Library ............. 21
- Immunology/Inflammation Compound Library ..................... 22
- JAK/STAT Compound Library ........................................... 23
- MAPK Compound Library ............................................... 24
- Membrane Transporter/Ion Channel Compound Library .......... 25
- Metabolism/Protease Compound Library .............................. 26
- Neuronal Signaling Compound Library ............................... 27
- NF-κB Signaling Compound Library .................................... 28
- PI3K/Akt/mTOR Compound Library ................................... 29
- Protein Tyrosine Kinase Compound Library ......................... 30
- Stem Cell Signaling Compound Library .............................. 31
- TGF-beta/Smad Compound Library .................................... 32
- Wnt/Hedgehog/Notch Compound Library ............................ 33

## According to Product Features:

- CNS-Penetrant Compound Library .................................... 11
- Natural Product Library .................................................. 12
- Toxins for Antibody-Drug Conjugate Research Library ......... 13
- Human Endogenous Metabolite Compound Library ............. 14

## Virtual Screening ....................................................... 34

- Inhibitors
- Agonists
- Screening Libraries
A unique collection of 5,259 bioactive compounds including natural products, enzyme inhibitors, receptor ligands, and drugs for high throughput screening (HTS) and high content screening (HCS).

- Bioactivity and safety confirmed by preclinical research and clinical trials. Some have been approved by FDA.
- Widely used in the research focus areas such as Cancer, Stem Cell, Neuronal Signaling, Immunity, and more.
- Structurally diverse, medicinally active, and cell permeable.
- More detailed compound information with structure, IC50, and other chemical & biological data.
- NMR and HPLC validated to ensure high purity and quality.
- All compounds are in stock and continuously updated.

### Targets Included in Bioactive Compound Library:

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bioactive Compound Library</td>
<td>HY-L001</td>
<td>5,259</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- 5-HT Receptor
- Angiotensin Receptor
- ATM/ATR
- CDK
- DNA/RNA Synthesis
- FGFR
- HIF/HIF Prolyl-Hydroxyylase
- IKK
- Microtubule/Tubulin
- P2X Receptor
- PD-1/PD-L1
- Phosphatase
- PKC
- Prostaglandin Receptor
- RAD51
- Reverse Transcriptase
- Sigma Receptor
- STING
- TGF-beta/Smad
- Thyroid Hormone Receptor
- Trytophan Hydroxylase
- Topoisomerase
- Vasopressin Receptor
- Xanthine Oxidase
- ACE
- Adenosine Receptor
- Adrenergic Receptor
- Akt
- Androgen Receptor
- ALK
- Antibacterial
- Antifolate
- Apoptosis
- Antiparasitic
- Aurora Kinase
- Bcl-2 Family
- Calcium Channel
- Casein Kinase
- Cannabinoid Receptor
- c-Kit
- c-Met/HGFR
- COX
- Cytochrome P450
- CXCR
- DNA Alkylator/Crosslinker
- DPP4
- Dopamine Receptor
- EGFR
- Epigenetic Reader Domain
- ERK
- Estrogen Receptor/ERR
- FLT3
- GABA Receptor
- GSK-3
- Glucocorticoid Receptor
- HCV
- HDAC
- HIV
- Histamine Receptor
- Histone Methyltransferase
- HSV
- IGF-1R
- JAK
- LRRK2
- mACHR
- MDM-2/p53
- MEK
- mGluR
- mTOR
- NF-κB
- NMDA Receptor
-OX Receptor
- Opioid Receptor
- p38 MAPK
- p97
- PAI-1
- PAK
- Parasite
- PARP
- PDGFR
- PDHK
- PDK-1
- PGE Synthase
- PERK
- P-glycoprotein
- PDE
- Phospholipase
- PI3K
- P4K
- Pim
- PKA
- Proteasome
- PAR
- Proton Pump
- Pyruvate Kinase
- PTEN
- Potassium Channel
- PPAR
- Progestrone Receptor
- Raf
- RAR/RXR
- Ras
- Ribosomal S6 Kinase (RSK)
- ROCK
- PAR
- PI
- Protease
- ROS
- RSV
- Ser/Thr Protease
- SGK
- Serotonin Transporter
- SGLT
- Sirtuin
- Smo
- Sodium Channel
- SPHK
- Sphingosine Phosphorylase
- STAT
- Syk
- Telomerase
- TOPK
- TGF-β Receptor
- TAM Receptor
- Toll-like Receptor (TLR)
- TNF Receptor
- TRP Channel
- Tyrosinase
- Trk Receptor
- ULK
- Urotensin Receptor
- URAT1
- VEGFR
- Wee1
- Wnt
- β-catenin
- γ-secretase
- ...
Bioactive Compound Library Plus

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bioactive Compound Library Plus</td>
<td>HY-L001P</td>
<td>7,428</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of 7,428 bioactive compounds including natural products, enzyme inhibitors, receptor ligands, and drugs for high throughput screening (HTS) and high content screening (HCS).
- The library consists of HY-L001 (Part A), compounds with low solubility or stability (Part B) and novel or rare compounds (Part C).
- Bioactivity and safety confirmed by preclinical research and clinical trials. Some have been approved by FDA.
- Widely used in the research focus areas such as Cancer, Stem Cell, Neuronal Signaling, Immunity, and more.
- Structurally diverse, medicinally active, and cell permeable.
- More detailed compound information with structure, IC50, and other chemical & biological data.
- NMR and HPLC validated to ensure high purity and quality.

<table>
<thead>
<tr>
<th>Part A</th>
<th>Part B</th>
<th>Part C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>5,259</td>
<td>630</td>
</tr>
<tr>
<td>Feature</td>
<td>General compounds (HY-L001)</td>
<td>Compounds with low solubility or stability</td>
</tr>
<tr>
<td>Package</td>
<td>Solution (10 mM) or solid (1 mg)</td>
<td>Only solid (1 mg)</td>
</tr>
</tbody>
</table>

Targeted Pathways of Bioactive Compounds

Clinical Phase for Bioactive Compounds

Publications Citing Use of MCE Bioactive Library Compounds:

...
Fragment Library

Cat. No.: HY-L032

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fragment Library</td>
<td>HY-L032</td>
<td>8,392</td>
<td>50 µL/well, 100 µL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of 8,392 fragment compounds for traditional lead identification via high-throughput screening (HTS).
- The compounds follow the Rule of Three.
- A useful tool for the fragment-based approach to drug discovery (FBDD).
- More detailed compound information with structure, Molecular Weight, cLogP, H-donor and H-acceptor number.
- NMR and HPLC validated ensure high purity.
- All compounds are in stock and continuously updated.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Range</th>
<th>Average Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Molecular Weight</td>
<td>≤300</td>
<td>179.20</td>
</tr>
<tr>
<td>cLogP</td>
<td>≤3.0</td>
<td>1.2944</td>
</tr>
<tr>
<td>H-donors</td>
<td>≤3.0</td>
<td>2.20</td>
</tr>
<tr>
<td>H-acceptors</td>
<td>≤3.0</td>
<td>0.81</td>
</tr>
</tbody>
</table>

Publications Citing Use of MCE Compound Screening Libraries:

- Nat Med. 2017 Apr 7;23(4):405-408.

...
FDA-Approved Drug Library

Cat. No.: HY-L022

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FDA-Approved Drug Library</td>
<td>HY-L022</td>
<td>1,619</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of 1,619 marketed drugs for high throughput screening (HTS) and high content screening (HCS).
- Used in the research of oncology, cardiology, anti-inflammatory, immunology, dermatology, endocrinology, neurology, and more.
- A useful tool for researching new targets of marketed old drugs.
- All compounds have been approved by the FDA or EMA.
- Structurally diverse, bioactive, and cell permeable.
- More detailed compound information with structure, IC50, and brief introduction.
- NMR and HPLC validated ensure high purity.
- All compounds are in stock and continuously updated.

### Targets Included in FDA-Approved Drug Library:

- **5 alpha Reductase**
- **5-HT Receptor**
- **ACE**
- **AChE**
- **Adenosine Receptor**
- **ALK**
- **Adrenergic Receptor**
- **Androgen Receptor**
- **Angiotensin Receptor**
- **Antibacterial**
- **Antifolate**
- **Antifungal**
- **Antiparasitic**
- **Autophagy**
- **Bcr-Abl**
- **Calcium Channel**
- **CaSR**
- **Carbonic Anhydrase**
- **c-Kit**
- **c-Met/HGFR**
- **Cytochrome P450**
- **CXCR**
- **DNA alkyator**
- **DPP4**
- **DNA/RNA Synthesis**
- **Dopamine Receptor**
- **EGFR**
- **Endothelin Receptor**
- **Estrogen Receptor**
- **Factor Xa**
- **GABA Receptor**
- **Glucocorticoid Receptor**
- **HBV**
- **HCN Channel**
- **HCV**
- **HDAC**
- **Histamine Receptor**
- **HIV**
- **HMG-CoA Reductase**
- **HSV**
- **Influenza Virus**
- **JAK**
- **Leukotriene Receptor**
- **mACHR**
- **mGlur**
- **Microtubule/Tubulin**
- **Monoamine Oxidase**
- **nACHR**
- **Neurokinin Receptor**
- **NMDA Receptor**
- **NNRTIs**
- **NRTIs**
- **Opioid Receptor**
- **P2Y Receptor**
- **PDE**
- **PDGFR**
- **PGE synthase**
- **Potassium Channel**
- **PKC**
- **Progesterone Receptor**
- **PPAR**
- **Proteasome**
- **Proton Pump**
- **Raf**
- **RAR/RXR**
- **Ras**
- **Sodium Channel**
- **SGLT**
- **Src**
- **SSRIs**
- **STAT**
- **Thrombin**
- **TNF-alpha**
- **Topoisomerase**
- **Vasopressin Receptor**
- **VEGFR**
- **Xanthine Oxidase**

### Publications Citing Use of MCE FDA-Approved Library Drugs:


...
FDA-Approved Drug Library Mini

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO)</th>
</tr>
</thead>
<tbody>
<tr>
<td>FDA-Approved Drug Library Mini</td>
<td>HY-L022M</td>
<td>1,559</td>
<td>10 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of 1,559 marketed drugs for high throughput screening (HTS) and high content screening (HCS).
- Used in the research of oncology, cardiology, anti-inflammatory, immunology, dermatology, endocrinology, neurology, and more.
- A useful tool for researching new targets of marketed old drugs.
- Easily peelable foil seal makes the screening process easier and faster.
- Lower price, more compounds.
- Avoid multiple and uneven dispensing.
- Reduce risks of product cross-contamination.
- Avoid reduced activity due to long-term storage.

<table>
<thead>
<tr>
<th>FDA-Approved Drug Library Mini</th>
<th>FDA-Approved Drug Library (Cat. No.: HY-L022)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Size</td>
<td>10 μL in DMSO</td>
</tr>
<tr>
<td>Package</td>
<td>30, 50, 100, and 250 μL in DMSO</td>
</tr>
<tr>
<td>Delivery Date</td>
<td>Within three days</td>
</tr>
<tr>
<td>Price Per Set</td>
<td>Low</td>
</tr>
<tr>
<td>Preparation For Use</td>
<td>Tear off the seal film on the microplate</td>
</tr>
<tr>
<td></td>
<td>If there is no robot, each tube needs to be manually opened</td>
</tr>
</tbody>
</table>

You can select:
- Specific Compounds
- Quantities
- Plate Map
- Concentration
- Format (Dry/Solid or DMSO Solution)
Clinical Compound Library

Cat. No.: HY-L026

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Compound Library</td>
<td>HY-L026</td>
<td>768</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of 768 clinical compounds for **high throughput screening (HTS)** and **high content screening (HCS)**.
- Research areas include **anticancer**, **anti-infection**, **anti inflammation**, **nervous disease**, and more.
- A useful tool for drug repurposing, the application of an existing therapeutic to a new disease indication.
- **Currently in clinical stage**, some are withdrawn or terminated.
- Structurally diverse, medicinally active, and cell permeable.
- Detailed compound information with structure, IC50, and brief introduction.
- Validated NMR and HPLC to ensure high purity and quality.
- All compounds are in stock and continuously updated.

Principle Research Areas of Clinical Compound Library

- Cancer
- Cardiovascular Disease
- Neurological Disease
- Inflammation/Immunology
- Metabolic Disease
- Endocrinology
- Infection
- Others

**Publications Citing Use of MCE Clinical Library Compounds:**

*Science*. 2017 Dec 1;358(6367).
...
### Anti-Cancer Compound Library

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-Cancer Compound Library</td>
<td>HY-L025</td>
<td>1,888</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of **1,888** bioactive anti-cancer compounds for **high throughput screening (HTS)** and **high content screening (HCS)**.
- Targets include kinases, cell cycle key components, tumorigenesis related signaling pathways, popular targets in epigenetic studies, and more.
- A useful tool for the **discovery of anti-cancer drugs**.
- Bioactivity and safety confirmed by preclinical research and clinical trials. Some have been approved by FDA.
- Structurally diverse, medicinally active, and cell permeable.
- Detailed compound information with structure, IC₅₀, and brief introduction.
- Validated NMR and HPLC to ensure high purity and quality.
- All compounds are in stock and continuously updated.

### Publications Citing Use of MCE Anti-Cancer Library Compounds:

- **Science.** 2018 Sep 28;361(6409).
- **Cell.** 2019 Jan 24;176(3):505-519.e22.
- **Cell.** 2018 Oct 4;175(2):442-457.e23.
- ...
Small Molecule Immuno-Oncology Compound Library

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Small Molecule Immuno-Oncology Compound Library</td>
<td>HY-L031</td>
<td>82</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of 82 bioactive tumor immunology compounds for high throughput screening (HTS) and high content screening (HCS).
- A useful tool for cancer research by activation of an antitumor immune response.
- Small molecule compounds targeting PD1/PD-L1, ROR, CCR, CXCR, Sting, IDO, TLR, etc.
- Bioactivity and safety confirmed by preclinical research and clinical trials, some have been approved by FDA.
- Structurally diverse, medicinally active, and cell permeable.
- More detailed compound information with structure, IC50, and other chemical & biological data.
- NMR and HPLC validated to ensure high purity and quality.
- All compounds are in stock and continuously updated.

Publications Citing Use of MCE Small Molecule Immuno-Oncology Library Compounds:

Nucleic Acids Res. 2018 Apr 20;46(7):3284-3297.
...
Anti-Infection Compound Library

Cat. No.: HY-L002

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-Infection Compound Library</td>
<td>HY-L002</td>
<td>561</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of 561 bioactive anti-infection compounds for high throughput screening (HTS) and high content screening (HCS).
- Targets such as Bacteria, Fungi, Parasite, CMV, HIV, SARS-CoV, Influenza Virus, etc.
- Bioactivity and safety confirmed by preclinical research and clinical trials, some have been approved by FDA.
- A useful tool to study infectious diseases or develop new anti-infection drugs.
- Structurally diverse, medicinally active, and cell permeable.
- More detailed compound information with structure, IC50, and other chemical & biological data.
- NMR and HPLC validated to ensure high purity and quality.
- All compounds are in stock and continuously updated.

Targets Included in Anti-Infection Compound Library:

<table>
<thead>
<tr>
<th>Antibacterial</th>
<th>Antifungal</th>
<th>Antiparasitic</th>
<th>CMV</th>
<th>Filovirus</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBV</td>
<td>HCV</td>
<td>HIV</td>
<td>HSV</td>
<td>Influenza Virus</td>
</tr>
<tr>
<td>NNRTIs</td>
<td>NRTIs</td>
<td>Rhinovirus (HRV)</td>
<td>RSV</td>
<td>SARS-CoV</td>
</tr>
</tbody>
</table>

Publications Citing Use of MCE Anti-Infection Library Compounds:

Science. 2017 Dec 1;358(6367).
...
Anti-Virus Compound Library

Cat. No.: HY-L027

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-Virus Compound Library</td>
<td>HY-L027</td>
<td>126</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of 126 bioactive anti-virus compounds for high throughput screening (HTS) and high content screening (HCS).
- Targets include HBV, HCV, HIV, HSV, Influenza Virus, Reverse Transcriptase, etc.
- A useful tool for the discovery of anti-virus drugs.
- Bioactivity and safety confirmed by preclinical research and clinical trials. Some have been approved by FDA.
- Structurally diverse, medicinally active, and cell permeable.
- Detailed compound information with structure, IC50, and brief introduction.
- Validated NMR and HPLC to ensure high purity and quality.
- All compounds are in stock and continuously updated.

### Targets Included in Anti-Virus Compound Library:

<table>
<thead>
<tr>
<th>CMV</th>
<th>HBV</th>
<th>HCV</th>
<th>HCV Protease</th>
<th>HIV</th>
<th>HIV Integrase</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIV Protease</td>
<td>HSV</td>
<td>Influenza Virus</td>
<td>NNRTIs</td>
<td>Reverse Transcriptase</td>
<td>RSV</td>
</tr>
</tbody>
</table>

📖 Publications Citing Use of MCE Anti-Virus Library Compounds:


...
CNS-Penetrant Compound Library

Cat. No.: HY-L028

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CNS-Penetrant Compound Library</td>
<td>HY-L028</td>
<td>328</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of 328 bioactive CNS-penetrant compounds for **high throughput screening (HTS)** and **high content screening (HCS)**.
- Targets such as **Kinases**, **GPCR** and **Ion Channels**, and more.
- A useful tool for the discovery of drugs used for **brain diseases**, such as brain tumors, mental disorders, and neurodegenerative diseases.
- Bioactivity and safety confirmed by preclinical research and clinical trials. Some inhibitors have been approved by FDA.
- Structurally diverse, medicinally active, CNS-penetrant and cell permeable.
- More detailed compound information with structure, ICS0, and brief introduction.
- NMR and HPLC validated to ensure high purity and quality.
- All compounds are in stock and continuously updated.

**Targets Included in CNS-Penetrant Compound Library:**

<table>
<thead>
<tr>
<th>5-HT Receptor</th>
<th>AChE</th>
<th>ADC Cytotoxin</th>
<th>Adenosine Receptor</th>
<th>Adrenergic Receptor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amyloid-β</td>
<td>Antibacterial</td>
<td>Antifolate</td>
<td>Antifungal</td>
<td>Antiparasitic</td>
</tr>
<tr>
<td>Bcr-Abl</td>
<td>Calcium Channel</td>
<td>Carbonic Anhydrase</td>
<td>CDK</td>
<td>c-Ki</td>
</tr>
<tr>
<td>COMT</td>
<td>COX</td>
<td>DNA Alkylator/Crosslinker</td>
<td>DNA/RNA Synthesis</td>
<td>Dopamine Receptor</td>
</tr>
<tr>
<td>EGFR</td>
<td>Estrogen Receptor/ERR</td>
<td>GABA Receptor</td>
<td>Histamine Receptor</td>
<td>HIV</td>
</tr>
<tr>
<td>HIV Protease</td>
<td>HMG-CoA Reductase</td>
<td>HSV</td>
<td>Influenza Virus</td>
<td>Melatonin Receptor</td>
</tr>
<tr>
<td>mGlur</td>
<td>mTOR</td>
<td>nAChR</td>
<td>Neurokinin Receptor</td>
<td>NMDA Receptor</td>
</tr>
<tr>
<td>NRTIs</td>
<td>Nucleoside Antimetabolite</td>
<td>p38 MAPK</td>
<td>PDE</td>
<td>PDGFR</td>
</tr>
<tr>
<td>PGE Synthase</td>
<td>Raf</td>
<td>Sodium Channel</td>
<td>Src</td>
<td>VEGFR</td>
</tr>
</tbody>
</table>

**Publications Citing Use of MCE CNS-Penetrant Library Compounds:**

- Cell. 2018 Sep 20;175(1):186-199.e19.
Natural Product Library

Cat. No.: HY-L021

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Natural Product Library</td>
<td>HY-L021</td>
<td>1,033</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of 1,033 natural products for high throughput screening (HTS) and high content screening (HCS).
- The compounds in the library contain Saccharides and Glycosides, Phenylpropanoids, Quinones, Flavonoids, Terpenoids and Glycosides, Steroids, Alkaloid, Phenols, Acids and Aldehydes.
- A useful tool for drug discovery as an important source of lead compounds.
- Bioactivity and safety confirmed by preclinical research and clinical trials. Some compounds have been approved by FDA.
- Structurally diverse, bioactive, and cell permeable.
- More detailed compound information with structure, IC50, and brief introduction.
- NMR and HPLC validated ensure high purity.
- All compounds are in stock and continuously updated.

Publications Citing Use of MCE Natural Library Products:

Science. 2017 Dec 1;358(6367).

...
Toxins for Antibody-Drug Conjugate Research Library

- A unique collection of 24 ADC cytotoxins for targeted therapy research.
- Used to develop new antibody-drug conjugates targeting cancer.
- Bioactivity and safety confirmed by preclinical research and clinical trials.
- Structurally diverse, medicinally active, and cell permeable.
- More detailed compound information with structure, IC50, and brief introduction.
- NMR and HPLC validated to ensure high purity and quality.
- All compounds are in stock and continuously updated.

Publications Citing Use of MCE Antibody-Drug Conjugate Research Library Toxins:

- Nat Med. 2017 Apr 7;23(4):405-408.
- J Control Release. 2018 May 10;277:23-34.

...
Human Endogenous Metabolite Compound Library

Cat. No.: HY-L030

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human Endogenous Metabolite Compound Library</td>
<td>HY-L030</td>
<td>322</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of 322 human endogenous metabolites for high throughput screening (HTS) and high content screening (HCS).
- The compounds derived from human issues with better bioavailability.
- A useful tool for metabonomics and metabolism-related drug discovery.
- Bioactivity and safety confirmed by preclinical research and clinical trials. Some compounds have been approved by FDA.
- Structurally diverse, bioactive, and cell permeable.
- More detailed compound information with structure, IC50, and brief introduction.
- NMR and HPLC validated ensure high purity.
- All compounds are in stock and continuously updated.

Publications Citing Use of MCE Human Endogenous Metabolite Library Compounds:


...
# Kinase Inhibitor Library

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kinase Inhibitor Library</td>
<td>HY-L009</td>
<td>860</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of **860** phosphorylation kinase inhibitors/regulators for **high throughput screening (HTS)** and **high content screening (HCS)**.
- The library contains compounds targeting **protein kinases** (VEGFR, EGFR, BTK, CDK, Akt, etc.), **lipid kinases** (PI3K, PI4K, SK, etc.) and **carbohydrate kinases** (Hexokinase).
- Kinase inhibitors have played an increasingly prominent role in the treatment of cancer and other diseases.
- Bioactivity and safety confirmed by preclinical research and clinical trials. Some inhibitors have been approved by FDA.
- Structurally diverse, medicinally active, and cell permeable.
- Rich documentation with structure, IC₅₀, and customer reviews.
- NMR and HPLC validated to ensure high purity.
- All compounds are in stock and continuously updated.

## Targets Included in Kinase Inhibitor Library:

<table>
<thead>
<tr>
<th>Targets Included in Kinase Inhibitor Library:</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACK1 Adenosine Kinase</td>
</tr>
<tr>
<td>Akt</td>
</tr>
<tr>
<td>ALK</td>
</tr>
<tr>
<td>AMPK</td>
</tr>
<tr>
<td>Aurora Kinase ATM/ATR</td>
</tr>
<tr>
<td>Axl Bcr-Abl BMX Kinase</td>
</tr>
<tr>
<td>Btk</td>
</tr>
<tr>
<td>CaMK-II Casein Kinase</td>
</tr>
<tr>
<td>CDK</td>
</tr>
<tr>
<td>c-Fms Checkpoint Kinase (Chk) c-Kit c-Met/HGFR</td>
</tr>
<tr>
<td>DAPK</td>
</tr>
<tr>
<td>DDR1/DDR2 Receptor DNA-PK</td>
</tr>
<tr>
<td>DLRK Ephrin Receptor EGFR ERK FAK FGFR FLT3</td>
</tr>
<tr>
<td>GSK-3 Glucokinase IGF-1R IKK Insulin Receptor IRAK</td>
</tr>
<tr>
<td>ITC Jak</td>
</tr>
<tr>
<td>JNK LIM Kinase(LIMK) MAPKAPK2 (MK2) MEK MELK</td>
</tr>
<tr>
<td>MNK Mixed Lineage Kinase p38 MAPK PAK PDGFR PDHK</td>
</tr>
<tr>
<td>P38 PERK PIK3 PIKfyve Pim PKA PKC</td>
</tr>
<tr>
<td>PKD Polo-like Kinase (PLK) Pyk2 Raf Ribosomal S6 Kinase RIK Kinase ROCK</td>
</tr>
<tr>
<td>ROCK</td>
</tr>
<tr>
<td>Ros1 Salt-inducible Kinases (SIKs) SGK SPHK Src SRPK Syk</td>
</tr>
<tr>
<td>TAK1 Trk Receptor ULK VEGFR Wee1 ...</td>
</tr>
</tbody>
</table>

## Publications Citing Use of MCE Kinase Library Inhibitors:

- **Science**. 2017 Dec 1;358(6367).
- **Cell**. 2018 Nov 1;175(4):984-997.e24.
- **Cell**. 2018 Oct 4;175(2):442-457.e23.
- **Cell**. 2018 Sep 20;175(1):171-185.e25.
- ...
Apoptosis Compound Library

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apoptosis Compound Library</td>
<td>HY-L003</td>
<td>137</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

• A unique collection of 137 small molecules used for survival, proliferation and apoptosis research.
• Targets such as Bcl-2 Family, Caspase, DAPK, IAP, MDM2/p53, PKD, Survivin, etc.
• Bioactivity and safety confirmed by preclinical research and clinical trials, some compounds have been approved by FDA.
• A useful tool to study apoptosis-involved regulation and diseases such as cancer, aging, neurodegenerative disease, and more.
• Structurally diverse, medicinally active, and cell permeable.
• More detailed compound information with structure, IC50, and other chemical & biological data.
• NMR and HPLC validated to ensure high purity and quality.
• All compounds are in stock and continuously updated.

<table>
<thead>
<tr>
<th>Targets Included in Apoptosis Compound Library:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Apoptosis</td>
</tr>
<tr>
<td>IAP</td>
</tr>
<tr>
<td>Thymidylate Synthase</td>
</tr>
<tr>
<td>TNF-alpha</td>
</tr>
</tbody>
</table>

📢 Publications Citing Use of MCE Apoptosis Library Compounds:

Cell Metab. 2019 Feb 14. pii: S1550-4131(19)30021-X.

...
Autophagy Compound Library

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autophagy Compound Library</td>
<td>HY-L029</td>
<td>510</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of 510 small molecule compounds with biological activity used for autophagy research and associated assays.
- Targets include Autophagy, LRRK2, and ULK.
- A useful tool for the research of autophagy-related regulation and diseases.
- Bioactivity and safety confirmed by preclinical research and clinical trials. Some have been approved by FDA.
- Structurally diverse, medicinally active, and cell permeable.
- Detailed compound information with structure, IC$_{50}$, and brief introduction.
- Validated NMR and HPLC to ensure high purity and quality.
- All compounds are in stock and continuously updated.

Targets Included in Autophagy Compound Library:
- Autophagy
- LRRK2
- ULK

Publications Citing Use of MCE Autophagy Library Compounds:

Cell. 2018 Sep 20;175(1):186-199.e19.
...
# Cell Cycle/DNA Damage Compound Library

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell Cycle/DNA Damage Compound Library</td>
<td>HY-L004</td>
<td>525</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of 525 Cell Cycle/DNA Damage related compounds for **high throughput screening (HTS)** and **high content screening (HCS)**.
- Targets such as **CDK**, **ROCK**, **Aurora Kinase**, **ATM/ATR**, **DNA-PK**, **DNA/RNA Synthesis**, etc.
- A useful tool to study the mechanism of cell cycle regulators that are critical to normal development and the development of **cancer**, **cardiovascular**, **inflammatory**, and **neurodegenerative diseases**.
- Bioactivity and safety confirmed by preclinical research and clinical trials. Some compounds have been approved by FDA.
- Structurally diverse, medicinally active, and cell permeable.
- More detailed compound information with structure, IC₅₀, and other chemical & biological data.
- All compounds are in stock and continuously updated.

### Targets Included in Cell Cycle/DNA Damage Compound Library:

<table>
<thead>
<tr>
<th>Antifolate</th>
<th>APC</th>
<th>ATM/ATR</th>
<th>Aurora Kinase</th>
<th>Casein Kinase</th>
</tr>
</thead>
<tbody>
<tr>
<td>CDK</td>
<td>Checkpoint Kinase (Chk)</td>
<td>CRISPR/Cas9</td>
<td>Deubiquitinase</td>
<td>DNA Alkylator/Crosslinker</td>
</tr>
<tr>
<td>DNA-PK</td>
<td>DNA/RNA Synthesis</td>
<td>G-quadruplex</td>
<td>Haspin Kinase</td>
<td>HDAC</td>
</tr>
<tr>
<td>HSP</td>
<td>Kinesin</td>
<td>KSP</td>
<td>LIM Kinase (LIMK)</td>
<td>Microtubule/Tubulin</td>
</tr>
<tr>
<td>Mps1</td>
<td>Nucleoside antimetabolite</td>
<td>p97</td>
<td>PAK</td>
<td>PARP</td>
</tr>
<tr>
<td>PERK</td>
<td>Polo-like Kinase (PLK)</td>
<td>PPAR</td>
<td>PTEN</td>
<td>RAD51</td>
</tr>
<tr>
<td>ROCK</td>
<td>Sirtuin</td>
<td>Telomerase</td>
<td>Topoisomerase</td>
<td>Wee1</td>
</tr>
</tbody>
</table>

### Publications Citing Use of MCE Cell Cycle/DNA Damage Library Compounds:


---

**Customize Library**

**You can select:**
- Specific Compounds
- Quantities
- Plate Map
- Concentration
- Format (Dry/Solid or DMSO Solution)
Epigenetics Compound Library

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epigenetics Compound Library</td>
<td>HY-L005</td>
<td>304</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of 304 small molecule modulators with biological activity used for epigenetics research and associated assays.
- The library contains epigenetics-related compounds targeting HDAC, Histone Demethylase, Histone Acetyltransferase (HAT), DNA Methyltransferase (DNMT), Epigenetic Reader Domain, MicroRNA, etc.
- A valuable tool for chemical genomics, epigenetic target identification in pharmacogenomics, and other biological applications.
- Bioactivity and safety confirmed by preclinical research and clinical trials. Some compounds have been approved by FDA.
- Structurally diverse, medicinally active, and cell permeable.
- Rich documentation with structure, IC50, and other chemical & biological data.
- NMR and HPLC validated to ensure the highest purity.
- All compounds are in stock and continuously updated.

Publications Citing Use of MCE Epigenetics Library Compounds:

Cell. 2018 Sep 20;175(1):186-199.e19.
...
**GPCR/G Protein Compound Library**

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GPCR/G Protein Compound Library</td>
<td>HY-L006</td>
<td>718</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of **718** small molecules targeting G protein coupled receptors used in GPCR screening for various research and drug development projects.
- Targets such as 5-HT Receptor, Dopamine Receptor, Opioid Receptor, Adrenergic Receptors, Cannabinoid Receptor, mGluR, ETA Receptor, etc.
- The most successful class of drugable targets in the human genome and remain the most attractive family of targets.
- All of the small molecules in the GPCR library are well characterized with biological and pharmaceutical activity. Some compounds have been approved by the FDA.
- A powerful tool for discovering GPCR-based drugs that are the richest signal receptor targets for drug discovery.
- Structurally diverse, medicinally active, and cell permeable.
- Rich documentation with structure, IC50, and brief introduction.
- NMR and HPLC validated to ensure the highest purity.
- All compounds are in stock and continuously updated.

**Targets Included in GPCR/G Protein Compound Library:**

<table>
<thead>
<tr>
<th>5-HT Receptor</th>
<th>Adenosine Receptor</th>
<th>Adiponectin Receptor</th>
<th>Adrenergic Receptor</th>
<th>Angiotensin Receptor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bombesin Receptor</td>
<td>Bradykinin Receptor</td>
<td>Cannabinoid Receptor</td>
<td>CaSR</td>
<td>CCR</td>
</tr>
<tr>
<td>CGRP Receptor</td>
<td>Cholecystokinin Receptor</td>
<td>CRTH2 (GPR44)</td>
<td>CXCR</td>
<td>Dopamine Receptor</td>
</tr>
<tr>
<td>EBI2/GPR183</td>
<td>Endothelin Receptor</td>
<td>GHSR</td>
<td>Glucagon Receptor</td>
<td>Glucocorticoid Receptor</td>
</tr>
<tr>
<td>GPR139</td>
<td>GPCR19</td>
<td>GPR109A</td>
<td>GPR119</td>
<td>GPR120</td>
</tr>
<tr>
<td>Imidazoline Receptor</td>
<td>Leukotriene Receptor</td>
<td>LPL Receptor</td>
<td>mAChR</td>
<td>Melatonin Receptor</td>
</tr>
<tr>
<td>mGluR</td>
<td>Motilin Receptor</td>
<td>Neurokinin Receptor</td>
<td>Neuropeptide Y Receptor</td>
<td>Neurotensin Receptor</td>
</tr>
<tr>
<td>Opioid Receptor</td>
<td>Orexin Receptor (OX Receptor)</td>
<td>P2Y Receptor</td>
<td>Prostaglandin Receptor</td>
<td>Protease-Activated Receptors (PARs)</td>
</tr>
<tr>
<td>Ras</td>
<td>RGS</td>
<td>Sigma Receptor</td>
<td>TSH Receptor</td>
<td>Vasopressin Receptor</td>
</tr>
</tbody>
</table>

**Publications Citing Use of MCE GPCR/G Protein Library Compounds:**


...
Histone Modification Research Compound Library

Cat. No.: HY-L024

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Histone Modification Research Compound Library</td>
<td>HY-L024</td>
<td>180</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of **180** bioactive compounds for high throughput screening (HTS) and high content screening (HCS).
- Targets include Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc.
- A useful tool for the research of the regulation of histone modification and the corresponding diseases.
- Bioactivity and safety confirmed by preclinical research and clinical trials. Some inhibitors have been approved by FDA.
- Structurally diverse, medicinally active, and cell permeable.
- More detailed compound information with structure, IC₅₀, and brief introduction.
- NMR and HPLC validated to ensure high purity and quality.
- All compounds are in stock and continuously updated.

**Publications Citing Use of MCE Histone Modification Research Library Compounds:**

- Cell. 2018 Sep 20;175(1):186-199.e19.
- ...

**Histone Modification Research Compound Library Composition**

- Epigenetic Reader Domain
- HDAC
- Histone Acetyltransferase
- Histone Demethylase
- Histone Methyltransferase
- Sirtuin
- ...

**Customize Library**

- You can select:
  - Specific Compounds
  - Quantities
  - Plate Map
  - Concentration
  - Format (Dry/Solid or DMSO Solution)
Immunology/Inflammation Compound Library

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunology/Inflammation Compound Library</td>
<td>HY-L007</td>
<td>263</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of 263 small molecules with biological activity used for Immunology/Inflammation research.
- The library contains compounds targeting Immunology/Inflammation-related enzyme such as CCR, COX, Interleukin Related, IRAK, MyD88, PDE, PD-1/PD-L1, TLR, and more.
- A useful tool for researching the mechanism behind Immunology/Inflammation, drug screening and other pharmaceutical and biological applications.
- Bioactivity and safety confirmed by preclinical research and clinical trials. Some compounds have been approved by FDA.
- Structurally diverse, medicinally active, and cell permeable.
- Rich documentation with structure, IC\textsubscript{50}, and brief introduction.
- NMR and HPLC validated to ensure high purity and quality.
- All compounds are in stock and continuously updated.

**Targets Included in Immunology/Inflammation Compound Library:**

<table>
<thead>
<tr>
<th>CCR</th>
<th>COX</th>
<th>Complement System</th>
<th>CRTH2 (GPR44)</th>
<th>CXCR</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLAP</td>
<td>Histamine Receptor</td>
<td>IFNAR</td>
<td>Interleukin Related</td>
<td>IRAK</td>
</tr>
<tr>
<td>MyD88</td>
<td>NO Synthase</td>
<td>NOD-like Receptors (NLRs)</td>
<td>PD-1/PD-L1</td>
<td>PGE Synthase</td>
</tr>
<tr>
<td>Salt-inducible Kinases (SIKs)</td>
<td>SPHK</td>
<td>STING</td>
<td>Thrombopoietin Receptor</td>
<td>Toll-like Receptor (TLR)</td>
</tr>
</tbody>
</table>

Publications Citing Use of MCE Immunology/Inflammation Library Compounds:


...
A unique collection of 123 bioactive compounds related to JAK/STAT signaling used for high throughput screening (HTS) and high content screening (HCS).

- Targets include JAK, STAT, EGFR, Pim, etc.
- A useful tool for JAK/STAT-related drug discovery.
- Bioactivity and safety confirmed by preclinical research and clinical trials. Some inhibitors have been approved by FDA.
- Structurally diverse, medicinally active, and cell permeable.
- More detailed compound information with structure, IC50, and brief introduction.
- NMR and HPLC validated to ensure high purity and quality.
- All compounds are in stock and continuously updated.

---

**JAK/STAT Compound Library**

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>JAK/STAT Compound Library</td>
<td>HY-L008</td>
<td>123</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

---

**Publications Citing Use of MCE JAK/STAT Library Compounds:**


...
MAPK Compound Library

Cat. No.: HY-L010

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MAPK Compound Library</td>
<td>HY-L010</td>
<td>120</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of 120 MAPK signaling inhibitors for high throughput screening (HTS) and high content screening (HCS).
- Targets such as ERK, JNK, MEK, p38 MAPK, Raf, RSK, etc.
- A useful tool for MAPK-related drug discovery and disease research.
- Bioactivity and safety confirmed by preclinical research and clinical trials. Some inhibitors have been approved by FDA.
- Structurally diverse, medicinally active, and cell permeable.
- More detailed compound information with structure, IC50, and brief introduction.
- NMR and HPLC validated to ensure high purity and quality.
- All compounds are in stock and continuously updated.

<table>
<thead>
<tr>
<th>Targets Included in MAPK Compound Library:</th>
</tr>
</thead>
<tbody>
<tr>
<td>ERK</td>
</tr>
<tr>
<td>JNK</td>
</tr>
<tr>
<td>KLF</td>
</tr>
<tr>
<td>MAPKAPK2 (MK2)</td>
</tr>
<tr>
<td>MEK</td>
</tr>
<tr>
<td>Mixed Lineage Kinase</td>
</tr>
<tr>
<td>MNK</td>
</tr>
<tr>
<td>p38 MAPK</td>
</tr>
<tr>
<td>Raf</td>
</tr>
<tr>
<td>Ribosomal S6 Kinase (RSK)</td>
</tr>
</tbody>
</table>

Publications Citing Use of MCE MAPK Library Compounds:

Science. 2017 Dec 1;358(6367).
Cancer Discov. 2018 Sep;8(9):1130-1141.
Sci Transl Med. 2019 Feb 6;11(478).
...
Membrane Transporter/Ion Channel Compound Library

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Membrane Transporter/Ion Channel Compound Library</td>
<td>HY-L011</td>
<td>422</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of 422 small molecule modulators used for Ion Channel and Membrane Transporter research.
- The library contains compounds targeting Membrane Transporters including Pgp, CRM1, BCRP, etc., and Ion Channels including CFTR, proton pump, sodium pump, calcium pump, etc.
- A useful tool for the research of drug absorption and distribution.
- Bioactivity and safety confirmed by preclinical research and clinical trials. Some inhibitors have been approved by FDA.
- Structurally diverse, medicinally active, and cell permeable.
- Rich documentation with structure, IC50, and summary.
- NMR and HPLC validated to ensure high purity.
- All compounds are in stock and continuously updated.

**Targets Included in Membrane Transporter/Ion Channel Compound Library:**

<table>
<thead>
<tr>
<th>ATP Synthase</th>
<th>BCRP</th>
<th>Calcium Channel</th>
<th>CFTR</th>
<th>Chloride Channel</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRAC Channel</td>
<td>CRM1</td>
<td>EAAT2</td>
<td>GABA Receptor</td>
<td>GlyT</td>
</tr>
<tr>
<td>HCN Channel</td>
<td>iGluR</td>
<td>Monoamine transporter</td>
<td>Monocarboxylate Transporter</td>
<td>Na+/Ca2+ Exchanger</td>
</tr>
<tr>
<td>Na+/HCO3− Cotransporter</td>
<td>Na+/K+ ATPase</td>
<td>nAChR</td>
<td>NKCC</td>
<td>P-glycoprotein</td>
</tr>
<tr>
<td>P2X Receptor</td>
<td>Potassium Channel</td>
<td>Proton Pump</td>
<td>SGLT</td>
<td>Sodium Channel</td>
</tr>
<tr>
<td>TRP Channel</td>
<td>URAT1</td>
<td>VDAC</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Publications Citing Use of MCE Membrane Transporter/Ion Channel Library Compounds:**

...
Metabolism/Protease Compound Library

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metabolism/Protease Compound Library</td>
<td>HY-L012</td>
<td>844</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of 844 Metabolism/Protease-related small molecules for high throughput screening (HTS) and high content screening (HCS).
- Targets such as PDE, Cytochrome P450, HMG-CoA Reductase, DPP4, Proteasome, HCV Protease, IDO, Cathepsin, MMP, etc.
- A useful tool for drug discovery of metabolism-related diseases.
- Bioactivity and safety confirmed by preclinical research and clinical trials. Some inhibitors have been approved by FDA.
- Structurally diverse, medicinally active, and cell permeable.
- More detailed compound information with structure, IC₅₀, and brief introduction.
- NMR and HPLC validated to ensure high purity and quality.
- All compounds are in stock and continuously updated.

**Targets Included in Metabolism/Protease Compound Library:**

<table>
<thead>
<tr>
<th>Cat. No.</th>
<th>Compounds</th>
</tr>
</thead>
<tbody>
<tr>
<td>HY-L012</td>
<td>Adenosine Deaminase</td>
</tr>
<tr>
<td></td>
<td>5 α-Reductase</td>
</tr>
<tr>
<td></td>
<td>5-Lipoxygenase</td>
</tr>
<tr>
<td></td>
<td>Angiotensin-converting Enzyme (ACE)</td>
</tr>
<tr>
<td></td>
<td>Aldose Reductase</td>
</tr>
<tr>
<td></td>
<td>Aldehyde Dehydrogenase (ALDH)</td>
</tr>
<tr>
<td></td>
<td>Aminopeptidase</td>
</tr>
<tr>
<td></td>
<td>Angiotensin-converting Enzyme (ACE)</td>
</tr>
<tr>
<td></td>
<td>Carboxypeptidase</td>
</tr>
<tr>
<td></td>
<td>Carboxypeptidase</td>
</tr>
<tr>
<td></td>
<td>Cathepsin</td>
</tr>
<tr>
<td></td>
<td>Cathepsin</td>
</tr>
<tr>
<td></td>
<td>Cytochrome P450</td>
</tr>
<tr>
<td></td>
<td>Cytochrome P450</td>
</tr>
<tr>
<td></td>
<td>Dipeptidyl Peptidase</td>
</tr>
<tr>
<td></td>
<td>Elastase</td>
</tr>
<tr>
<td></td>
<td>E1/E2/E3 Enzyme</td>
</tr>
<tr>
<td></td>
<td>FAAH</td>
</tr>
<tr>
<td></td>
<td>Factor Xa</td>
</tr>
<tr>
<td></td>
<td>Fatty Acid Synthase</td>
</tr>
<tr>
<td></td>
<td>DGAT</td>
</tr>
<tr>
<td></td>
<td>Glucokinase</td>
</tr>
<tr>
<td></td>
<td>HCV Protease</td>
</tr>
<tr>
<td></td>
<td>HIF/HIF Prolyl-Hydroxylase</td>
</tr>
<tr>
<td></td>
<td>HIV Integrase</td>
</tr>
<tr>
<td></td>
<td>HIV Protease</td>
</tr>
<tr>
<td></td>
<td>HMG-CoA Reductase (HMGCR)</td>
</tr>
<tr>
<td></td>
<td>HSP</td>
</tr>
<tr>
<td></td>
<td>Indoleamine 2,3-Dioxygenase (IDO)</td>
</tr>
<tr>
<td></td>
<td>Isocitrate Dehydrogenase (IDH)</td>
</tr>
<tr>
<td></td>
<td>MAGL</td>
</tr>
<tr>
<td></td>
<td>MMP</td>
</tr>
<tr>
<td></td>
<td>Nampt</td>
</tr>
<tr>
<td></td>
<td>PAI-1</td>
</tr>
<tr>
<td></td>
<td>Phosphodiesterase (PDE)</td>
</tr>
<tr>
<td></td>
<td>Procollagen C Proteinase</td>
</tr>
<tr>
<td></td>
<td>Proteasome</td>
</tr>
<tr>
<td></td>
<td>Pyruvate Dehydrogenase</td>
</tr>
<tr>
<td></td>
<td>Renin</td>
</tr>
<tr>
<td></td>
<td>Ser/Thr Protease</td>
</tr>
<tr>
<td></td>
<td>Stearoyl-CoA Desaturase (SCD)</td>
</tr>
<tr>
<td></td>
<td>Thrombin</td>
</tr>
<tr>
<td></td>
<td>Tryptophan Hydroxylase</td>
</tr>
<tr>
<td></td>
<td>Tyrosinase</td>
</tr>
<tr>
<td></td>
<td>Xanthine Oxidase</td>
</tr>
<tr>
<td></td>
<td>...</td>
</tr>
</tbody>
</table>

**Publications Citing Use of MCE Metabolism/Protease Library Compounds:**

Science. 2018 Sep 28;361(6409).
Cell Host Microbe. 2018 Sep 12;24(3):353-363.e5.
...
Neuronal Signaling Compound Library

- A unique collection of 511 Neuronal Signaling-related compounds for high throughput screening (HTS) and high content screening (HCS).
- Targets such as 5-HT Receptor, AChE, Adrenergic Receptor, AMPAR, Beta-secretase, Dopamine Receptor, FAAH, Melatonin Receptor, AChR, Opioid Receptor, γ-secretase, etc.
- A useful tool for the research of neuronal regulation and neuronal diseases.
- Bioactivity and safety confirmed by preclinical research and clinical trials. Some inhibitors have been approved by FDA.
- Structurally diverse, medicinally active, and cell permeable.
- More detailed compound information with structure, IC50, and brief introduction.
- NMR and HPLC validated to ensure high purity and quality.
- All compounds are in stock and continuously updated.

### Targets Included in Neuronal Signaling Compound Library:

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuronal Signaling Compound Library</td>
<td>HY-L013</td>
<td>511</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

### Publications Citing Use of MCE Neuronal Signaling Library Compounds:

- **Sci Transl Med.** 2019 Feb 6;11(478).
- ...
NF-κB Signaling Compound Library

Cat. No.: HY-L014

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NF-κB Signaling Compound Library</td>
<td>HY-L014</td>
<td>88</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of 88 NF-κB signaling related small molecule compounds for high throughput screening (HTS) and high content screening (HCS).
- Targets such as IKK, Keap1-Nrf2, NF-κB, etc.
- A powerful tool for researching the mechanism behind cancer, drug screening based on NF-κB signaling pathway and other pharmaceutical and biological applications.
- Bioactivity and safety confirmed by preclinical research and clinical trials. Some inhibitors have been approved by FDA.
- Structurally diverse, medicinally active, and cell permeable.
- More detailed compound information with structure, IC₅₀, and brief introduction.
- NMR and HPLC validated to ensure high purity and quality.
- All compounds are in stock and continuously updated.

Publications Citing Use of MCE NF-κB Signaling Library Compounds:


...
PI3K/Akt/mTOR Compound Library

Cat. No.: HY-L015

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PI3K/Akt/mTOR Compound Library</td>
<td>HY-L015</td>
<td>174</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of 174 small molecule inhibitors used for PI3K/Akt/mTOR pathway research.
- Targets such as Akt, AMPK, DNA-PK, PDK-1, mTOR, PI3K, PTEN, etc.
- A valuable tool for studying PI3K/Akt/mTOR-related survival, proliferation, and apoptosis of cells and related diseases.
- Bioactivity and safety confirmed by preclinical research and clinical trials. Some inhibitors have been approved by the FDA.
- Structurally diverse, medicinally active, and cell permeable.
- Rich documentation with structure, IC50, and summary.
- NMR and HPLC validated to ensure high purity.
- All compounds are in stock and continuously updated.

**Targets Included in PI3K/Akt/mTOR Compound Library:**

<table>
<thead>
<tr>
<th>Akt</th>
<th>AMPK</th>
<th>ATM/ATR</th>
<th>DNA-PK</th>
<th>GSK-3</th>
<th>MELK</th>
</tr>
</thead>
<tbody>
<tr>
<td>mTOR</td>
<td>PDK-1</td>
<td>PI3K</td>
<td>PI4K</td>
<td>PIKfyve</td>
<td>PTEN</td>
</tr>
</tbody>
</table>

**Publications Citing Use of MCE PI3K/Akt/mTOR Library Compounds:**


...
Protein Tyrosine Kinase Compound Library

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protein Tyrosine Kinase Compound Library</td>
<td>HY-L016</td>
<td>327</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of 327 protein kinase inhibitors for high throughput screening (HTS) and high content screening (HCS).
- Targets such as VEGFR, ALK, Btk, Bcr-Abl, c-Met/HGFR, EGFR, FGFR, Insulin Receptor, JAK, PDGFR, etc.
- A useful tool for the research for PTK-related diseases, such as cancer.
- Bioactivity and safety confirmed by preclinical research and clinical trials. Some protein kinase inhibitors have been approved by FDA.
- Structurally diverse, medicinally active and cell permeable.
- Rich documentation with structure, IC50 and summary.
- NMR and HPLC to ensure the high purity.
- All compounds are in stock and continuously updated.

**Targets Included in Protein Tyrosine Kinase Compound Library:**

<table>
<thead>
<tr>
<th>Ack1</th>
<th>ALK</th>
<th>Bcr-Abl</th>
<th>BMX Kinase</th>
<th>Btk</th>
<th>c-Fms</th>
</tr>
</thead>
<tbody>
<tr>
<td>c-Kit</td>
<td>c-Met/HGFR</td>
<td>Discoidin Domain Receptor</td>
<td>DYRK</td>
<td>EGFR</td>
<td>Ephrin Receptor</td>
</tr>
<tr>
<td>FAK</td>
<td>FGFR</td>
<td>FLT3</td>
<td>IGF-1R</td>
<td>Insulin Receptor</td>
<td>IRAK</td>
</tr>
<tr>
<td>Itk</td>
<td>PDGFR</td>
<td>PKA</td>
<td>Pyk2</td>
<td>ROS</td>
<td>Src</td>
</tr>
<tr>
<td>Syk</td>
<td>TAM Receptor</td>
<td>Trk Receptor</td>
<td>VEGFR</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Publications Citing Use of MCE Protein Tyrosine Kinase Library Compounds:**

- *Science*. 2017 Dec 1;358(6367).
...
Stem Cell Signaling Compound Library

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stem Cell Signaling Compound Library</td>
<td>HY-L017</td>
<td>210</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of 210 small molecule inhibitors with biological activity used for stem cell regulatory and signaling pathway research.
- Targets such as GSK-3, Hedgehog, Notch, JAK, ROCK, Wnt, γ-secretase, Casein Kinase, etc.
- A powerful tool for researching the mechanism behind stem cells, regenerative therapy, drug screening based on tumor stem cells, as well as other pharmaceutical and biological applications.
- Bioactivity and safety confirmed by preclinical research and clinical trials. Some protein kinase inhibitors have been approved by FDA.
- Structurally diverse, medicinally active, and cell permeable.
- Rich documentation with structure, IC50, and customer reviews.
- NMR and HPLC validated to ensure the highest purity.
- All compounds are in stock and continuously updated.

Targets Included in Stem Cell Signaling Compound Library:

<table>
<thead>
<tr>
<th>Casein Kinase</th>
<th>ERK</th>
<th>Gli</th>
<th>GSK-3</th>
<th>Hedgehog</th>
<th>Hippo (MST)</th>
</tr>
</thead>
<tbody>
<tr>
<td>JAK</td>
<td>Notch</td>
<td>Oct3/4</td>
<td>PKA</td>
<td>Porcupine</td>
<td>ROCK</td>
</tr>
<tr>
<td>sFRP-1</td>
<td>Smo</td>
<td>STAT</td>
<td>TGF-beta/Smad</td>
<td>Wnt</td>
<td>YAP</td>
</tr>
<tr>
<td>β-catenin</td>
<td>γ-secretase</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Publications Citing Use of MCE Stem Cell Signaling Library Compounds:

**TGF-beta/Smad Compound Library**

Cat. No.: HY-L018

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TGF-beta/Smad Compound Library</td>
<td>HY-L018</td>
<td>63</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of 63 TGF-beta/Smad inhibitors for high throughput screening (HTS) and high content screening (HCS).
- Targets include PKC, ROCK, TGF-beta/Smad, and TGF-β Receptor.
- A useful tool for researching TGF-beta/Smad-related regulation and diseases.
- Bioactivity and safety confirmed by preclinical research and clinical trials. Some inhibitors have been approved by FDA.
- Structurally diverse, medicinally active, and cell permeable.
- More detailed compound information with structure, IC50, and brief introduction.
- NMR and HPLC validated to ensure high purity and quality.
- All compounds are in stock and continuously updated.

---

**Publications Citing Use of MCE TGF-beta/Smad Library Compounds:**

 Biomaterials. 2018 Dec 6;193:30-46.
...

---

**TGF-beta/Smad Compound Library Composition**

- PKC
- TGF-β Receptor
- ROCK
- TGF-beta/Smad

---

---
# Wnt/Hedgehog/Notch Compound Library

**Cat. No.: HY-L020**

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Cat. No.</th>
<th>Compounds</th>
<th>Size (Pre-dissolved in DMSO/Solid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wnt/Hedgehog/Notch Compound Library</td>
<td>HY-L020</td>
<td>95</td>
<td>30 μL/well, 50 μL/well, 100 μL/well, 250 μL/well (10 mM solution)</td>
</tr>
</tbody>
</table>

- A unique collection of 95 small molecule inhibitors with biological activity used for Wnt/Hedgehog/Notch pathway research and screening.
- Targets include Notch, Gli, GSK-3, Hedgehog, Porcupine, sFRP-1, Smo, Wnt, β-catenin, etc.
- A useful tool for the research of Wnt/Hedgehog/Notch-related regulation and diseases.
- Bioactivity and safety confirmed by preclinical research and clinical trials. Some inhibitors have been approved by FDA.
- Structurally diverse, medicinally active, and cell permeable.
- More detailed compound information with structure, IC_{50}, and brief introduction.
- All compounds are in stock and continuously updated.

## Targets Included in Wnt/Hedgehog/Notch Compound Library:

<table>
<thead>
<tr>
<th>Casein Kinase</th>
<th>Gli</th>
<th>GSK-3</th>
<th>Hedgehog</th>
<th>Notch</th>
<th>Porcupine</th>
</tr>
</thead>
<tbody>
<tr>
<td>sFRP-1</td>
<td>Smo</td>
<td>TGF-beta/Smad</td>
<td>Wnt</td>
<td>YAP</td>
<td>β-catenin</td>
</tr>
</tbody>
</table>

***Publications Citing Use of MCE Wnt/Hedgehog/Notch Library Compounds:***


...
Virtual Screening

Virtual screening is a computational technique used to search libraries of small molecules in order to identify those structures which are most likely to bind to a drug target. Nowadays, it has become a crucial step in early-stage drug discovery owing to its unique advantages over experimental HTS: drug target-relevant, competitive price and efficient.

MedChemExpress (MCE) provides high quality virtual screening service that enables researchers to identify most promising candidates.

The virtual screening methods are mainly divided into two types: structure-based virtual screening (SBVS) and ligand-based virtual screening (LBVS).

• **SBVS**
  
The general scheme of a SBVS strategy starts with processing the 3D target structural information of pharmaceutical protein interested (determined either experimentally or computationally through homology modeling) and then dock the small molecules to targeted binding sites. These docked compounds are then ranked based on their predicted binding affinity or complementarity to the binding site, as well as other criteria. Usually only a few top-ranked compounds are selected as candidates for further experimental assays. Our fast and accurate ligand docking and scoring procedures lead to efficient virtual screening.

• **LBVS**
  
In the absence of 3D structures of potential drug targets, LBVS is one of the most popular approaches for drug discovery and lead optimization. Biological data are explored in order to identify known active or inactive compounds that will be used to retrieve other potentially active molecular scaffolds for experimental evaluation. LBVS methods include approaches such as similarity and substructure searching, quantitative structure-activity relationships (QSAR), pharmacophore mapping, and machine learning.

Advantages:

• Ligand-based and structure-based virtual screening
• Super high-performance computer
• Compound database containing over 2 million purchasable compounds
• 3D pharmacophore model building
• Consideration of water and solvation effects
<table>
<thead>
<tr>
<th>Product Name</th>
<th>Compounds</th>
<th>Features</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCE Bioactive Compound Library</td>
<td>7,428</td>
<td>A unique collection of 7,428 bioactive and structurally diverse compounds. Bioactivity and safety confirmed by preclinical research and clinical trials. Some have been approved by FDA.</td>
</tr>
<tr>
<td>MCE Fragment Library</td>
<td>8,392</td>
<td>Latest release of Ro3 Fragment Library comprising over 8,392 high-quality molecules. A useful tool for the fragment-based approach to drug discovery (FBDD).</td>
</tr>
<tr>
<td>HTS Compound Library</td>
<td>1,938,649</td>
<td>Enamine HTS Collection contains 1,938,649 diverse screening compounds. These compounds frequently have unusual structures and unique properties. The collection is particularly recommended for the researchers looking for most diverse screening set.</td>
</tr>
<tr>
<td>Advanced Library</td>
<td>531,580</td>
<td>Enamine Advanced Collection contains 531,580 compounds that have lead-like properties with MW ≤ 350, ClogP ≤ 3, and RotBonds ≤ 7 and/or valuable pharmacophores such carboxylic, primary amino and amide groups.</td>
</tr>
<tr>
<td>Premium Library</td>
<td>138,801</td>
<td>Enamine Premium Collection contains over 138,801 compounds having most favorable molecular properties (high Fsp3, low logP and MW).</td>
</tr>
<tr>
<td>Agro-like Library</td>
<td>15,085</td>
<td>Library of compounds intended for use in agro/crop science.</td>
</tr>
<tr>
<td>Allosteric GPCR Library</td>
<td>17,385</td>
<td>A sub-library of Enamine’s GPCR Library designed for discovery of novel allosteric ligands.</td>
</tr>
<tr>
<td>Allosteric Kinase Library</td>
<td>5,678</td>
<td>Carefully selected molecules via docking and visual evaluation.</td>
</tr>
<tr>
<td>Antiviral Library</td>
<td>3,700</td>
<td>Nucleoside-like compounds able to act as antiviral.</td>
</tr>
<tr>
<td>Aquaporins Library</td>
<td>1,500</td>
<td>A unique collection of 1,500 bioactive compounds targeting aquaporins.</td>
</tr>
<tr>
<td>BACE Library</td>
<td>7,171</td>
<td>The library was designed to find molecules which target Beta-secretase (BACE).</td>
</tr>
<tr>
<td>CNS Library</td>
<td>47,040</td>
<td>Library of novel small molecules with high CNS MPO scores.</td>
</tr>
<tr>
<td>Covalent Screening Library</td>
<td>21,969</td>
<td>A set of screening compounds bearing “warheads” for covalent target modification.</td>
</tr>
<tr>
<td>Discovery Diversity Set 10</td>
<td>10,240</td>
<td>Enamine Discovery Diversity Sets (DDS) are high-quality compound libraries focused on novel chemotypes and non-trivial structures. They compose of DDS-10 (10,240 compounds) and DDS-50 (50,240 compounds) sets which do not overlap. Discovery Diversity Set 10 contains 10,240 diverse screening compounds.</td>
</tr>
<tr>
<td>Discovery Diversity Set 50</td>
<td>50,240</td>
<td>Enamine Discovery Diversity Sets (DDS) are high-quality compound libraries focused on novel chemotypes and non-trivial structures. They compose of DDS-10 (10,240 compounds) and DDS-50 (50,240 compounds) sets which do not overlap. Discovery Diversity Set 50 contains 50,240 diverse screening compounds.</td>
</tr>
<tr>
<td>DNA Library</td>
<td>5,530</td>
<td>Designed for identification of new actives against proteins essential for DNA stability.</td>
</tr>
<tr>
<td>Epigenetics Library</td>
<td>9,353</td>
<td>Library of compounds focusing to hit on a number of epigenetic targets.</td>
</tr>
<tr>
<td>Glycomimetic Library</td>
<td>2,718</td>
<td>Specially synthesized set of compounds able to mimic glycosides and their interaction with proteins.</td>
</tr>
<tr>
<td>GPCR Library</td>
<td>54,077</td>
<td>Designed for discovery of new GPCR ligands.</td>
</tr>
<tr>
<td>Hit Locator Library 200</td>
<td>200,000</td>
<td>Enamine Hit Locator Library (HLL) is a sizable highly diverse screening set of 500,160 novel screening compounds. Hit Locator Library 200 (Core Set) contains 200,000 core compounds.</td>
</tr>
<tr>
<td>Hit Locator Library 500</td>
<td>500,160</td>
<td>Enamine Hit Locator Library (HLL) is a sizable highly diverse screening set of 500,160 novel screening compounds. Hit Locator Library 500 (Entire Set) contains 500,160 compounds.</td>
</tr>
<tr>
<td>IDO Targeted Library</td>
<td>5,502</td>
<td>IDO focused library designed by a combination of structure- and ligand-based methods.</td>
</tr>
<tr>
<td>Immuno-Oncology Library</td>
<td>52,935</td>
<td>Designed for discovery of novel hits in Immuno-Oncology therapeutic area.</td>
</tr>
<tr>
<td>Ion Channel Library</td>
<td>30,418</td>
<td>Designed for discovery of new Ion Channels ligands.</td>
</tr>
<tr>
<td>Protein-Protein Interaction Library</td>
<td>59,370</td>
<td>Designed for discovery of novel PPI inhibitors.</td>
</tr>
<tr>
<td>Specs HTS Compounds Library</td>
<td>210,454</td>
<td>Specs HTS library is a unique collection contains 210,454 diverse screening compounds for the lead identification via high-throughput screening (HTS) and high content screening (HCS).</td>
</tr>
</tbody>
</table>
### About Us

#### Overview of MedChemExpress

MedChemExpress (MCE) offers a wide range of high quality research chemicals and biochemicals including novel life-science reagents, reference compounds, APIs and natural compounds for laboratory and scientific use. MCE has knowledgeable and friendly customer service and technical support teams with years of experience in the life science industry. MCE will be a competent and trustworthy partner for your research and scientific projects.

#### Quality

Product quality is the key to our success and we take pride in offering only the highest-grade products. Product identity, quality, purity and activity are assured by our robust quality control and assurance polices, programs and procedures. We perform thorough analytical testing - including HNMR, LC-MS and HPLC - stability testing and activity assays on our products and the results from these tests are available to clients.

#### Experience

Our chemists are highly experienced in molecular synthesis and the preparation of large quantities of structurally diverse and synthetically challenging molecules. We work with clients that have widely different needs and we have been very successful in meeting such needs.

#### Services

We offer:

- Structurally and synthetically diverse biologically active compounds
- Flexible order volume ranging from milligrams to kilograms scale
- On-time delivery of products

We are a client-centric company and are always looking to hearing from you about how our products and services might better assist you.

---

For More Product Information, Please Visit Us Online
